Tag: lucrative
Bristol Myers Squibb’s Zeposia angles for lucrative ulcerative colitis nod with...
Bristol Myers Squibb notched a big win with its recent approval of multiple sclerosis drug Zeposia, a Celgene pipeline pickup with blockbuster aspirations. Not content to ride its...